New Medical Therapies in Inflammatory Bowel Diseases In 2017

Keywords

Inflammatory bowel disease, Medicine, Inflammatory Bowel Diseases, Intensive care medicine, Tumor necrosis factor alpha

References

• Recent developments in the treatment of inflammatory bowel diseaseSvend T. Rietdijk, Geert D’Haens — 2013
• Review article: infliximab for Crohn’s disease treatment – shifting therapeutic strategies after 10 years of clinical experienceSilvio Danese, J F Colombel, Walter Reinisch — 2011
• New targets for mucosal healing and therapy in inflammatory bowel diseasesMarkus F. Neurath — 2013
• Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.Paul Rutgeerts, Gert Van Assche, William J. Sandborn — 2012
• New Drug Therapies on the Horizon for IBDClémentine Perrier, Paul Rutgeerts — 2012
• Vedolizumab as induction and maintenance therapy for Crohn's disease.William J. Sandborn, Brian G. Feagan, Paul Rutgeerts — 2013
• Ustekinumab induction and maintenance therapy in refractory Crohn's disease.William J. Sandborn, Christopher Gasink, Long-Long Gao — 2012
• Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus reportBrian G. Feagan, Marc Lémann, Ragnar Befrits — 2012
• Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.Guillaume Bouguen — 2011
• Infliximab, azathioprine, or combination therapy for Crohn's disease.Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch — 2010
• New therapies for inflammatory bowel disease: from the bench to the bedsideSilvio Danese — 2011
• Medical Therapy Update in Crohn’s DiseaseAtilla Ertan — 2014
• Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.Lucine Vuitton, Stéphane Koch, Laurent Peyrin‐Biroulet — 2013
• The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY ConsortiumParambir S. Dulai, Siddharth Singh, Xiaoqian Jiang — 2016
• Novel Therapies in Inflammatory Bowel Disease: An Evaluation of the EvidenceNeeraj Narula, David T. Rubin, Bruce E. Sands — 2016
• Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms.Jean‐Frédéric Colombel, Uma Mahadevan — 2017
• Ustekinumab for Crohn's Disease.Reena Khanna, Waqqas Afif — 2017
• Inflammatory bowel disease.Eva Szigethy, Laura P. McLafferty, Alka Goyal — 2011

Cited by

No citing papers recorded for this paper.

Related papers

• Origins and Directions of Inflammatory Bowel Disease, Early Studies of the “Nonspecific” Inflammatory Bowel DiseasesJoel S. Levine — 2003
• Neonatal interleukin-1β (IL1β) and tumor necrosis factor-α (TNF): Circulating levels and cellular production1989
• A 5-year study on hospital discharges for pediatric inflammatory bowel diseases in LombardiaC. De Giacomo, Chiara Moretti, Elisabetta Stacul — 2015
• Mo1835 PREVALENCE OF OCULAR DISEASES IN INFLAMMATORY BOWEL DISEASE (IBD): A NATIONAL, POPULATION-BASED STUDYDayyan Adoor, Mohammed Z. Sheriff, Emad Mansoor — 2020
• Requirement for the continual presence of lipopolysaccharide for production of tumor necrosis factor by thioglycollate‐induced peritoneal murine macrophagesGeorge E. Gifford, Marie‐Luise Lohmann‐Matthes — 1986
• Tissue heterogeneity in the production of tumor necrosis factor (TNF) by rat macrophages1989
• Effect of tumor necrosis factor-α on the nitric oxide level in cultured osteoblasts in vitroH Ji — 2013
• Effects of tumor necrosis factor (TNF) and immunotherapy directed against TNF on rat cardiac transplants.Seu P, Imagawa Dk, Olthoff Km — 1991
• 0796 Tumor Necrosis Factor-α(TNF)はウィルス心筋炎の防御に必須である : TNFノックアウトマウス(TNF-KO)を用いての検討久泰 和田, 邦明 斉藤, 満 清島 — 1999
• 825 GLUCOCORTICOIDS, BUT NOT PRIOR EXERCISE, SUPPRESS THE LIPOPOLYSACCHARIDE-INDUCED TUMOR NECROSIS FACTOR (TNF) RESPONSE IN WHOLE BLOODR. E. Shepherd, D P Mokry, Larry D. Crouch — 1994